Cytosorbents Corp Form 8-K Summary
Business Context and Reporting Period
Cytosorbents Corporation (Nasdaq: CTSO) filed this Current Report on Form 8-K on June 9, 2020. The filing reports a significant corporate event under Item 8.01 Other Events.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial figure disclosed is the value of a new contract award.
Material Changes
The Company was awarded a Defense Health Agency Small Business Technology Transfer (STTR) Phase III contract. Key details include:
- Contract Value: Up to $2,897,172.
- Duration: 2 years.
- Purpose: To advance the HemoDefend-BGA plasma and whole blood adsorber to human clinical trials.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future performance, or specific risk factors beyond the context of the contract award. The primary focus is the progression of the HemoDefend-BGA product into human clinical trials.
Investor Verification Checklist
- Verify the terms and milestones of the STTR Phase III contract in the attached press release (Exhibit 99.1).
- Confirm the timeline for the initiation of human clinical trials for HemoDefend-BGA.
- Review subsequent filings for any financial impact or revenue recognition related to this contract.